These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10097082)

  • 1. Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization.
    Mateu MG; Fersht AR
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3595-9. PubMed ID: 10097082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.
    Stavridi ES; Chehab NH; Caruso LC; Halazonetis TD
    Protein Sci; 1999 Sep; 8(9):1773-9. PubMed ID: 10493578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
    Lubin DJ; Butler JS; Loh SN
    J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meanfield approach to the thermodynamics of a protein-solvent system with application to the oligomerization of the tumor suppressor p53.
    Noolandi J; Davison TS; Volkel AR; Nie X; Kay C; Arrowsmith CH
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):9955-60. PubMed ID: 10944184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and functionality of a designed p53 dimer.
    Davison TS; Nie X; Ma W; Lin Y; Kay C; Benchimol S; Arrowsmith CH
    J Mol Biol; 2001 Mar; 307(2):605-17. PubMed ID: 11254385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain.
    Mateu MG; Fersht AR
    EMBO J; 1998 May; 17(10):2748-58. PubMed ID: 9582268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
    Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
    Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refined solution structure of the oligomerization domain of the tumour suppressor p53.
    Clore GM; Ernst J; Clubb R; Omichinski JG; Kennedy WM; Sakaguchi K; Appella E; Gronenborn AM
    Nat Struct Biol; 1995 Apr; 2(4):321-33. PubMed ID: 7796267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking.
    Stommel JM; Marchenko ND; Jimenez GS; Moll UM; Hope TJ; Wahl GM
    EMBO J; 1999 Mar; 18(6):1660-72. PubMed ID: 10075936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
    Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
    Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solvent-exposed residues located in the beta-sheet modulate the stability of the tetramerization domain of p53--a structural and combinatorial approach.
    Mora P; Carbajo RJ; Pineda-Lucena A; Sánchez del Pino MM; Pérez-Payá E
    Proteins; 2008 Jun; 71(4):1670-85. PubMed ID: 18076077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tandem dimerization of the human p53 tetramerization domain stabilizes a primary dimer intermediate and dramatically enhances its oligomeric stability.
    Poon GM; Brokx RD; Sung M; Gariépy J
    J Mol Biol; 2007 Jan; 365(4):1217-31. PubMed ID: 17113101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive evolution of p53 thermodynamic stability.
    Khoo KH; Andreeva A; Fersht AR
    J Mol Biol; 2009 Oct; 393(1):161-75. PubMed ID: 19683006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of tetramerization in p53 function.
    Chène P
    Oncogene; 2001 May; 20(21):2611-7. PubMed ID: 11420672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meanfield approach to the thermodynamics of protein-solvent systems with application to p53.
    Völkel AR; Noolandi J
    Biophys J; 2001 Mar; 80(3):1524-37. PubMed ID: 11222313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.
    Clore GM; Omichinski JG; Sakaguchi K; Zambrano N; Sakamoto H; Appella E; Gronenborn AM
    Science; 1994 Jul; 265(5170):386-91. PubMed ID: 8023159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidation of methionine residue at hydrophobic core destabilizes p53 tetrameric structure.
    Nomura T; Kamada R; Ito I; Chuman Y; Shimohigashi Y; Sakaguchi K
    Biopolymers; 2009 Jan; 91(1):78-84. PubMed ID: 18781628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A stable human p53 heterotetramer based on constructive charge interactions within the tetramerization domain.
    Brokx RD; Bolewska-Pedyczak E; Gariépy J
    J Biol Chem; 2003 Jan; 278(4):2327-32. PubMed ID: 12433927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural investigations of the p53/p73 homologs from the tunicate species Ciona intestinalis reveal the sequence requirements for the formation of a tetramerization domain.
    Heering J; Jonker HR; Löhr F; Schwalbe H; Dötsch V
    Protein Sci; 2016 Feb; 25(2):410-22. PubMed ID: 26473758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.